Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease At study entry, patients should have a clinical diagnosis of FCAS, MWS or NOMID and require medication. At the time of screening, patients can be either untreated or treated with other medication. 2. Presence, or history of at least 2 of the following symptoms For NOMID patients Typical NOMID urticarial rash Signs of central nervous system (CNS) involvement such as increased intracranial pressure and/or papilledema and/or cerebral spinal fluid pleiocytosis and/or stroke and/or seizures, and/or sensorineural hearing loss Typical arthropatic changes on X-rays: epiphysal and/or patellar overgrowth With start of NOMID symptoms before or at 6 months of age For MWS patients periodic fever headache/migraine arthralgia urticarial skin rash  Pregnant or nursing (lactating) women. 2. All women capable of becoming pregnant unless they are postmenopausal or are using one or more methods of contraception. 3. Participation in any other study within 30 days 4. Infection with HIV, Hepatitis B or C. 5. Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose. 6. History of drug or alcohol abuse within the 12 months prior to dosing. 7. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing for adults. 8. History of significant medical conditions, which in the doctor's opinion would the patient from participating in this trial. 9. History of renal transplantation. 10. Presence of any additional rheumatic diseases or significant systemic diseases. For example, major chronic infectious/ inflammatory/ immunologic disease (such as inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, systemic lupus erythematosus in addition to the autoinflammatory disease). 11. Presence of any of the following laboratory abnormalities: ALT or AST greater than 2 times the upper limit of normal (ULN), platelet count less than 100x109/L. 12. History of recurrent and/or evidence of clinically significant active bacterial, fungal, or viral infections. 13. History of contact with patients with suspected tuberculosis symptoms; or history or complication of tuberculosis infection. 14. Use of the following therapies Etanercept in the 4 weeks prior to the baseline visit (Day 1) and thereafter Adalimumab in the 8 weeks prior to the baseline visit (Day 1) and thereafter Infliximab in the 12 weeks prior to the baseline visit (Day 1) and thereafter Rituximab in the 26 weeks prior to the baseline visit (Day 1) and thereafter Tocilizumab in the 3 weeks prior to the baseline visit (Day 1) and thereafter Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1) and thereafter (with the exception of anakinra therapy-see below) Anakinra therapy after the baseline visit (Day 1). Last anakinra injection should occur not less than 6 hours prior to the canakinumab injection at Day 1 Leflunomide in the 4 weeks prior to the baseline visit (Day 1) and thereafter. After the completion of leflunomide treatment a cholestiramine in dose 8 g 3 times per day for 14 days is recommended Thalidomide in the 4 weeks prior to the baseline visit (Day 1) and thereafter